Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc., commonly referred to as Valeant, is a prominent player in the global pharmaceutical industry, headquartered in the United States. Founded in 1960, the company has established a significant presence in various operational regions, including North America, Europe, and Asia. Valeant focuses on specialty pharmaceuticals and over-the-counter products, with a diverse portfolio that includes dermatology, ophthalmology, and neurology. The company is known for its innovative approach to drug development and its commitment to addressing unmet medical needs. Valeant's unique offerings, such as its advanced dermatological treatments and specialty pharmaceuticals, have positioned it as a leader in the market. With a history of strategic acquisitions and a robust pipeline, Valeant continues to achieve notable milestones, solidifying its reputation as a key player in the pharmaceutical landscape.
DitchCarbon Score
How does Valeant Pharmaceuticals International, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Valeant Pharmaceuticals International, Inc.'s score of 20 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Valeant Pharmaceuticals International, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Bausch Health Companies Inc., which means that any emissions data or climate commitments would be inherited from this parent organisation. Bausch Health Companies Inc. has not publicly disclosed specific reduction targets or initiatives related to carbon emissions, nor have they committed to any climate pledges. As a result, Valeant Pharmaceuticals does not have defined emissions reduction strategies or targets at this time. Given the lack of specific emissions data and reduction initiatives, it is important to note that the pharmaceutical industry is increasingly focusing on sustainability and climate commitments. Companies are encouraged to adopt science-based targets and participate in initiatives such as the Science Based Targets initiative (SBTi) to align with global climate goals. In summary, Valeant Pharmaceuticals International, Inc. currently lacks detailed emissions data and specific climate commitments, relying on the broader sustainability framework established by its parent company, Bausch Health Companies Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 46,686,000 | 00,000,000 |
| Scope 2 | 50,513,000 | 00,000,000 |
| Scope 3 | 19,260,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Valeant Pharmaceuticals International, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
